¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö : 2018-11-16

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö : 2018-11-16
±³À°ÀÏÀÚ : 2018-11-16
±³À°Àå¼Ò : °­¸ª¾¾¸¶Å©È£ÅÚ ¾Æ»êÆ®¸®¿ò  
±³À°ÁÖÁ¦ : Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
´ã´çÀÚ : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
¿¬¶ôó : 02-794-2630  
À̸ÞÀÏ : webmaster@rheum.or.kr      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Á¤Çü¿Ü°ú, Áø´Ü°Ë»çÀÇÇаú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : °­¿øµµ
±³À°½Ã°£ : 11 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í : ȸ¿ø Àü¹®ÀÇ, ÀüÀÓÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø »çÀüµî·Ï 60,000¿ø, ÇöÀåµî·Ï 80,000¿øȸ¿ø Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø ¿Ü »çÀüµî·Ï 40,000¿ø, ÇöÀåµî·Ï 60,000¿øºñȸ¿ø Àü¹®ÀÇ, ÀüÀÓÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø »çÀüµî·Ï 80,000¿ø, ÇöÀåµî·Ï 100,000¿øºñȸ¿ø Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø ¿Ü »çÀüµî·Ï 50,000¿ø, ÇöÀåµî·Ï 70,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 09:00~09:30 Validation of FRAX for osteoporosis treatment decision in patients with osteoarthritis: A multicenter comparative study of FRAX criteria and WHO criteria  ±èº¸¿µ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 09:30~10:00 Angiogenesis using smart material  ±è¼º°ï(°­¸ª¿øÁÖ´ë Ä¡´ë ±¸°­¾Ç¾È¸é¿Ü°úÇÐ) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 10:00~10:30 Ãµ¿¬¹°À» ÀÌ¿ëÇÑ °ñ´Ù°øÁõ Ä¡·áÁ¦ °³¹ß  À¯ÁöÇý(KIST) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 11:00~11:40 Systemic and local fat in knee osteoarthritis.  Changhai Ding(Univ. of Tasmania, Australia) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 11:20~12:00 Management of systemic sclerosis -current status and future directions  Masataka Kuwana(Nippon Medical School, Japan) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 12:10~12:40 ICHOM standard set of outcomes that matter to patients suffering from inflammatory arthritis, explaining the goal of ICHOM, the methodology and how to apply this global development Mart  A.F.J van de Laar(University of Twente, the Netherlands) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 13:30~13:50 What¡¯s the choice after failure of first anti-TNF in RA?  Â÷ÈƼ®(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 13:50~14:10 To taper or not to taper biologics in RA?  ½É½Âö(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 14:10~14:30 Can we stop progression of structural damage in axial SpA?  ±è¿ë±æ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 14:30~14:50 Do we need to supplement vitamin D in autoimmune rheumatic diseases?  ±è±ÙÅÂ(°í½ÅÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 15:30~15:50 New therapy in SLE: is the glass half-full or half-empty?  ¼­Ã¢Èñ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 15:50~16:10 Can we withdraw Immunosuppressants in patients with lupus nephritis in remission?  ¼ºÀ±°æ(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 16:10~16:30 Do we still need biopsy to diagnose Sjögren¡¯s syndrome?  °û½Â±â(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 16:30~16:50 How can we better manage interstitial lung disease in systemic sclerosis?  ÀÌÀººÀ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 09:00~09:30 ÀÓ»óÁø·áÁöħ °³¹ß °³¿ä¿Í ±âȹ  ±èÀç±Ô(Áß¾ÓÀÇ´ë, ´ëÇÑÀÇÇÐȸ Á¤Ã¥ÀÌ»ç) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 09:30~09:50 Áø·áÁöħ °³¹ß °æÇè-GIOP¿Í ¿¹¹æÁ¢Á¾À» Áß½ÉÀ¸·Î  ÀüÂùÈ«(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 09:50~10:05 Áø·áÁöħ °³¹ß Çʿ伺-·ù¸¶Æ¼½º °üÀý¿°  ÀÌÁö¼ö(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 10:05~10:20 Ã༺ôÃß°üÀý¿°-°­Á÷ôÃß¿° Ä¡·á±Ç°í °³¹ß  ¹éÇÑÁÖ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 13:30~14:00 Is it possible to prevent RA?  ÀÌ»óÀÏ(°æ»óÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 14:00~14:30 The cellular and molecular mechanisms in cartilage degeneration  Çѽ¿ì(°æºÏÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 14:30~15:00 CAR-T cells beyond cancer: A new therapy for autoimmune diseases?  Á¤ÁØÈ£(¼­¿ïÀÇ´ë »ýÈ­Çб³½Ç) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 15:30~16:00 Epigenetic control of immune cells.  ±è¶ô±Õ(¿¬¼¼ÀÇ´ë ÀÇ»ý¸í°úÇкÎ) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 16:00~16:30 Follicular helper T cell.  ÃÖÀ±¼ö(¼­¿ïÀÇ´ë ÀÇ°úÇаú) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 16:30~17:00 Chronic/persistent infection and autoimmune diseases  ÃÖ¿µ´Ô(¼­¿ïÄ¡Àü¿ø ±¸°­¹Ì»ý¹°Çб³½Ç) 
±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 13:30~13:50 ·ù¸¶Æ¼½º°üÀý¿°ÀÇ Áúº´È°¼ºµµ ÃøÁ¤.  ÀÌâÈÆ(¿ø±¤ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 13:50~14:10 °­Á÷ôÃß¿°ÀÇ Áúº´È°¼ºµµ ÃøÁ¤.  ÀÌ»ó¿ø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 14:10~14:30 °í½ÄÀû ÇÕ¼º Ç×·ù¸¶Æ¼½ºÁ¦Á¦(csDMARDs) ¾Ë¾Æº¸±â  ±èÇö¼÷(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 14:30~14:50 ·ù¸¶Æ¼½º ÁúȯÀÇ Ç¥ÀûÄ¡·áÁ¦.  È«½ÂÀç(°æÈñÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö : 2018-11-16""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 4Â÷»ê¾÷Çõ¸í°ú ³ëÈ­¿¬±¸ÀÇ ¹Ì·¡ (ÀüºÏÀÇ´ë »ýÈ­Çб³½Ç ±èÁ¾¼® ±³¼ö) / °¨¼ºÀ¸·Î ½Î¿ö¶ó -º´¿ø°æ¿µ(¹éâÈñ) : 2018-11-17
´ÙÀ½±Û Ãæ³²´ëÇб³º´¿ø ´ëÀüÁö¿ª¾Ï¼¾ÅÍ È¯ÀÚ¿ì¼±ÀÇ °íÇ°°Ý ¾ÏÁø·á ½ÉÆ÷Áö¾ö : ´ÙÇÐÁ¦ ÅëÇÕÁø·á : 2018-11-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
92 ¼­¿ï 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-08-24 0 305 2018-07-28
91 ¼­¿ï 2018³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãß°èÇмú´ëȸ(8/24) : 2018-08-24 0 322 2018-07-28
90 ÀÎõ °­È­±ºÀÇ»çȸ 3Â÷ ¼¼¹Ì³ª(°üÀýº¸Á¸ Ä¡·á) : 2018-08-24 0 315 2018-07-28
89 °æ±â Á¦5Â÷ ¾Æ½Ã¾ÆºÎÀÎÁ¾¾çÇÐȸ ¿öÅ©¼ó(ASGO 5th International Workshop on Gynecologic Oncology in conjunction with 12th KSGO Workshop for Young Gynecologic Oncologists) : 2018-08-24 0 482 2018-07-28
88 ¼­¿ï ´ëÇÑÀÇ»çÇùȸ [Á¦27±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤] °Ç°­º¸Çè°ú ¹Î°£ÀǷẸÇè : 2018-08-23 0 295 2018-07-28
87 ¼­¿ï ±¹¸³ÀÇ·á¿ø 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-08-23 0 368 2018-07-28
86 ¼­¿ï ±¹¸³ÀÇ·á¿ø 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-08-22 0 475 2018-07-28
85 ¼­¿ï ´ëÇÑÀÓ»óÅëÁõÇÐȸ 2018³â Á¦2ȸ Á¤±âÇмúÁý´ãȸ : 2018-08-22 0 438 2018-07-28
84 °æºÏ ´ëÇÑôÃ߽Űæ¿Ü°úÇÐȸ ´ë±¸°æºÏÁöȸ Á¦4Â÷ Áõ·ÊÅä·Ðȸ : 2018-08-21 0 421 2018-07-28
83 Ãæ³² ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ ´ëÀüÃæûÁöȸ 8¿ù ¿¬¼ö°­Á : 2018-08-21 0 380 2018-07-28
82 °­¿ø ±¹¸³ÀÇ·á¿ø °ø°øÀÇ·á Consensus conference(3Â÷: °­¿ø±Ç) : 2018-08-20 0 436 2018-07-28
81 ¼­¿ï 2018³âµµ ´ëÇÑÅëÁõÇÐȸ ¾à¹°Ä¡·á ¿¬¼ö°­Á : 2018-08-19 0 485 2018-07-28
80 ¼­¿ï Á¦16ȸ ±è¾È°úº´¿ø ½ÉÆ÷Áö¾ö : 2018-08-19 1 777 2018-07-28
79 ¼­¿ï 2018 ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ °³¿ø¼¼¹Ì³ª : 2018-08-19 0 696 2018-07-28
78 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø Á¦7ȸ ¿°Áõ¼º ÀåÁúȯ ¼¾ÅÍ ½ÉÆ÷Áö¾ö : 2018-08-19 0 333 2018-07-28
1401 | 1402 | 1403 | 1404 | 1405 | 1406 | 1407 | 1408 | 1409 | 1410
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷